Does contraception cause hair loss? It's a question many people in the UK ask when they notice increased shedding after starting or changing a contraceptive method. The answer is nuanced: some hormonal contraceptives can contribute to hair loss in certain individuals, but this is not universal. The type of hair loss, the specific contraceptive involved, and individual hormonal sensitivity all play important roles. This article explores the evidence, explains how hormones affect the hair growth cycle, outlines which contraceptives carry the greatest risk, and offers practical guidance on what to do if you are concerned.

Can Hormonal Contraceptives Cause Hair Loss?

Yes, some hormonal contraceptives can contribute to hair loss, most commonly telogen effluvium or, in genetically predisposed women, androgenetic alopecia — though this is not a universal side effect.

Experiencing these side effects? Our pharmacists can help you navigate them →

Hormonal contraceptives are among the most widely used medications in the UK, and questions about their potential side effects — including hair loss — are common. The short answer is that yes, some hormonal contraceptives can contribute to hair loss in certain individuals, though this is not a universal experience and the relationship is more nuanced than a straightforward cause and effect.

It is also important to recognise that hair shedding can have many causes — including nutritional deficiencies, thyroid disorders, and stress — which may coincide with a change in contraception and should be assessed alongside any potential hormonal contribution.

The type of hair loss most commonly associated with hormonal contraceptives is telogen effluvium — a temporary, diffuse shedding of hair that occurs when a significant number of hair follicles shift prematurely into the resting (telogen) phase of the growth cycle. Telogen effluvium does not cause permanent follicle damage and is usually reversible. It can be triggered by hormonal fluctuations, including those caused by starting, stopping, or switching contraceptive methods.

A second, less common form is androgenetic alopecia (female-pattern hair loss), which involves progressive follicle miniaturisation and may be unmasked or accelerated in women who have a genetic predisposition to it. Certain progestogens found in some contraceptives have androgenic (testosterone-like) activity, which can potentially contribute to this type of hair thinning.

Not sure if this is normal? Chat with one of our pharmacists →

Hair loss (alopecia) is listed as a recognised adverse reaction — typically in the 'uncommon' or 'rare' frequency category — in the Summary of Product Characteristics (SmPC) for several hormonal contraceptive products, including the levonorgestrel intrauterine system (Mirena), the etonogestrel implant (Nexplanon), and the medroxyprogesterone acetate injection (Depo-Provera), as well as various combined oral contraceptives. Much of this evidence comes from post-marketing surveillance reports rather than controlled trials. If you suspect your contraceptive is affecting your hair, speaking to a GP or pharmacist is a sensible first step. You can also report suspected side effects through the MHRA Yellow Card Scheme (yellowcard.mhra.gov.uk).

Which Types of Contraceptive Are Most Commonly Linked to Hair Loss?

Progestogens with higher androgenic activity, such as levonorgestrel and norethisterone, carry the greatest risk; anti-androgenic pills containing drospirenone or cyproterone acetate may actually reduce hair loss in susceptible women.

Not all contraceptives carry the same risk of hair loss. The likelihood depends largely on the type and androgenic potency of the progestogen used, the degree of systemic hormonal exposure, and the individual's hormonal sensitivity.

Progestogen-only methods — including the progestogen-only pill (POP, sometimes called the 'mini pill'), the hormonal intrauterine system (IUS, e.g., Mirena), the contraceptive implant (Nexplanon), and the injectable contraceptive (Depo-Provera) — may be associated with hair thinning in susceptible individuals, though the evidence varies by product. It is worth noting that the levonorgestrel IUS (Mirena) releases very low levels of hormone locally, resulting in minimal systemic exposure; nonetheless, alopecia is listed as an uncommon adverse reaction in its SmPC. The degree of risk with progestogen-only methods depends on the specific progestogen, its androgenic activity, and individual sensitivity, rather than being a class effect.

Combined oral contraceptives (COCs), which contain both oestrogen and a progestogen, present a more complex picture:

• Pills containing more androgenic progestogens (such as levonorgestrel or norethisterone) may be more likely to contribute to hair loss in susceptible women.

• Pills containing low-androgenic progestogens such as desogestrel (used in some COCs) have a reduced androgenic effect compared with levonorgestrel or norethisterone.

• Pills containing anti-androgenic progestogens (such as drospirenone or cyproterone acetate) may actually help reduce hair loss in some women, particularly those with conditions such as polycystic ovary syndrome (PCOS).

It is also worth noting that stopping a combined pill can itself trigger a temporary episode of telogen effluvium, as the body readjusts to its natural hormonal rhythm. This shedding typically begins two to four months after discontinuation and usually resolves within six to twelve months without treatment.

FSRH guidance notes that levonorgestrel- and norethisterone-containing COCs are associated with a lower risk of venous thromboembolism (VTE) than some other formulations — a factor relevant when weighing up contraceptive choices. Individual risk assessment with a clinician is always recommended.

How Hormones Affect the Hair Growth Cycle

Oestrogen prolongs the anagen (growth) phase and is hair-protective, while androgens can miniaturise follicles in genetically predisposed individuals; hormonal fluctuations from contraceptives can disrupt this cycle.

To understand why contraceptives can influence hair, it helps to appreciate how hormones interact with the hair growth cycle. Hair follicles are highly sensitive to hormonal signals, and even modest changes in hormone levels can alter the timing and duration of each growth phase.

The hair growth cycle consists of three main phases:

• Anagen — the active growth phase, lasting two to seven years

• Catagen — a short transitional phase lasting a few weeks

• Telogen — the resting phase, lasting around three months, after which the hair sheds

Oestrogen is generally considered hair-protective. It prolongs the anagen phase, which is why many women notice thicker, fuller hair during pregnancy when oestrogen levels are high. Conversely, a drop in oestrogen — such as after childbirth or when stopping a combined pill — can push a large proportion of follicles into telogen simultaneously, resulting in noticeable shedding. Importantly, telogen effluvium does not cause follicle miniaturisation and is distinct from androgenetic alopecia; it is usually fully reversible once the underlying trigger is addressed.

Androgens, including testosterone and dihydrotestosterone (DHT), can miniaturise hair follicles over time in genetically predisposed individuals, leading to progressively finer and shorter hairs — the hallmark of androgenetic alopecia. Progestogens with androgenic activity can mimic this effect to varying degrees. The enzyme 5-alpha reductase, which converts testosterone to the more potent DHT, is present in scalp follicles and plays a central role in androgenetic alopecia. Understanding this mechanism helps explain why the choice of progestogen in a contraceptive can make a meaningful difference to hair health in susceptible women.

The British Association of Dermatologists (BAD) provides patient information leaflets on both telogen effluvium and female-pattern hair loss, which offer further detail on these distinct conditions.

Managing Hair Loss While Using Contraception

First-line management includes ruling out iron deficiency and thyroid dysfunction with blood tests; do not stop or switch contraception without speaking to a GP, and allow six to twelve months for visible improvement.

If you notice increased hair shedding or thinning after starting or changing a contraceptive, there are several practical steps that may help manage the situation.

First, assess the timeline. Hair loss related to hormonal changes often has a delay of two to four months. Keeping a simple diary of when you started your contraceptive and when shedding began can help your GP identify a potential link.

Do not stop or switch your contraceptive without speaking to a GP or sexual health clinician first. If a change is recommended, ensure effective alternative contraception is in place during any transition.

Nutritional assessment is an important consideration. Deficiencies in iron (ferritin) and thyroid function are the most common treatable contributors to hair loss in women and should be assessed first. A GP can arrange blood tests — typically a full blood count (FBC), ferritin, and thyroid function tests (TFTs) — as a starting point, in line with NICE CKS and BAD guidance. Testing for vitamin D, zinc, B vitamins, or hormone profiles is not routinely first-line and should only be arranged if there is a specific clinical indication. Do not take supplements unless a deficiency has been confirmed or your clinician advises it, as over-supplementation carries its own risks.

In terms of hair care:

• Avoid excessive heat styling, tight hairstyles, and harsh chemical treatments

• Use a gentle, sulphate-free shampoo

• Consider a wide-toothed comb to reduce mechanical breakage

Topical minoxidil is a licensed treatment for female-pattern hair loss in the UK. It is available over the counter (e.g., as a 2% solution or 5% foam for women). It is not recommended during pregnancy or breastfeeding, and some individuals experience scalp irritation or a temporary increase in shedding when first starting treatment. Discuss suitability with a GP or dermatologist before use, particularly if you are of childbearing age.

In many cases, hair loss associated with contraceptives is temporary and self-limiting. Patience is often required, as the hair growth cycle means visible improvement may take six to twelve months even after the underlying cause has been addressed.

When to Speak to a GP or Pharmacist

Seek GP advice promptly if hair loss is sudden, patchy, accompanied by other symptoms, or causing significant distress; first-line investigations include FBC, ferritin, and thyroid function tests.

Whilst some degree of hair shedding is normal — losing up to 100 hairs per day is considered within the typical range — there are circumstances where professional advice should be sought promptly.

Contact your GP if you notice:

• Sudden or rapidly progressive hair loss

• Patchy hair loss (which may suggest alopecia areata, an autoimmune condition)

• Hair loss accompanied by other symptoms such as fatigue, weight changes, irregular periods, or skin changes (which could indicate a thyroid disorder or PCOS)

• New-onset hirsutism (excess facial or body hair), severe acne, or other signs of hyperandrogenism

• Significant scalp changes, including redness, scaling, or scarring

• Hair loss that is causing significant psychological distress

A GP will typically take a thorough history and may arrange blood tests to rule out underlying causes. In line with NICE CKS and BAD guidance, first-line investigations usually include a full blood count (FBC), ferritin, and thyroid function tests. Androgen profiles (e.g., testosterone, sex hormone-binding globulin, prolactin) are generally reserved for women with features of hyperandrogenism, menstrual irregularity, or clinical suspicion of PCOS or another endocrine disorder.

Your pharmacist can also be a valuable first point of contact. They can review your current contraceptive and any other medications for potential interactions or side effects, and advise on whether a GP referral is appropriate.

If hair loss is confirmed to be linked to your contraceptive, your GP can discuss switching to an alternative formulation. For persistent or complex cases, referral to a NHS dermatologist is the appropriate specialist pathway. Private trichologists are not NHS-regulated and are not part of the standard NHS referral pathway; if you choose to consult one privately, ensure your GP remains involved in your care.

If you believe your hair loss may be a side effect of your contraceptive, you can report this through the MHRA Yellow Card Scheme (yellowcard.mhra.gov.uk).

Alternative Contraceptive Options If Hair Loss Is a Concern

Switching to a combined pill with an anti-androgenic progestogen or using a hormone-free copper IUD are the main alternatives, but VTE risk and individual health factors must be assessed with a clinician.

If you and your GP agree that your current contraceptive may be contributing to hair loss, there are several alternatives worth considering. The right choice will depend on your overall health, contraceptive needs, individual risk factors, and personal preferences.

Switching to a combined pill with an anti-androgenic progestogen is often the first option explored. Combined pills containing ethinylestradiol/drospirenone or co-cyprindiol (cyproterone acetate/ethinylestradiol) have anti-androgenic properties and may help reduce hair loss in women with androgenetic alopecia or PCOS. However, important caveats apply:

• Ethinylestradiol/drospirenone carries a higher risk of venous thromboembolism (VTE) compared with levonorgestrel- or norethisterone-containing COCs. This risk must be assessed individually in line with FSRH guidance and the UK Medical Eligibility Criteria (UKMEC).

• Co-cyprindiol is licensed primarily for the treatment of severe acne and/or hirsutism in women, not as a first-line contraceptive. It should not be prescribed solely for contraception, requires periodic review, and also carries a higher VTE risk than standard levonorgestrel-containing COCs. It should be stopped three to four cycles after the condition being treated has resolved.

FSRH guidance recommends that, where VTE risk is a consideration, levonorgestrel- or norethisterone-containing COCs are generally preferred as first-line combined hormonal contraception.

Non-hormonal contraceptive methods eliminate hormonal influence on hair entirely and may be suitable for some women:

• Copper intrauterine device (IUD) — highly effective, hormone-free, and long-acting; there is no established link between the copper IUD and hair loss

• Barrier methods such as condoms or a diaphragm (cap), used with or without spermicide

Ultimately, contraceptive choice is deeply personal and should be made collaboratively with a healthcare professional. The Faculty of Sexual and Reproductive Healthcare (FSRH) provides up-to-date UK guidance on contraceptive options, and your GP or sexual health clinic can help you weigh the benefits and risks of each method in the context of your individual health history. Do not stop your current contraceptive without first discussing an alternative plan with a clinician.

Frequently Asked Questions